GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Enterprise Value

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Enterprise Value : $-24.44 Mil (As of May. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Reneo Pharmaceuticals's Enterprise Value is $-24.44 Mil. Reneo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-76.50 Mil. Therefore, Reneo Pharmaceuticals's EV-to-EBIT ratio for today is 0.32.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Reneo Pharmaceuticals's Enterprise Value is $-24.44 Mil. Reneo Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-76.35 Mil. Therefore, Reneo Pharmaceuticals's EV-to-EBITDA ratio for today is 0.32.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Reneo Pharmaceuticals's Enterprise Value is $-24.44 Mil. Reneo Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Reneo Pharmaceuticals's EV-to-Revenue ratio for today is .


Reneo Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Reneo Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals Enterprise Value Chart

Reneo Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 61.42 -42.16 -48.52

Reneo Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.70 80.27 133.46 -48.52 -26.45

Competitive Comparison of Reneo Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Reneo Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reneo Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reneo Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Reneo Pharmaceuticals's Enterprise Value falls into.



Reneo Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Reneo Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Reneo Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reneo Pharmaceuticals  (NAS:RPHM) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Reneo Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-24.444/-76.497
=0.32

Reneo Pharmaceuticals's current Enterprise Value is $-24.44 Mil.
Reneo Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.50 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Reneo Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-24.444/-76.352
=0.32

Reneo Pharmaceuticals's current Enterprise Value is $-24.44 Mil.
Reneo Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.35 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Reneo Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-24.444/0
=

Reneo Pharmaceuticals's current Enterprise Value is $-24.44 Mil.
Reneo Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reneo Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Executives
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse officer: Senior VP, Corporate Operation C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam officer: VP of Finance & Administration C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher director 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal officer: Chief Financial Officer C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher director, officer: President and CEO 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson officer: Chief Development Officer 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p. 10 percent owner 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106